News
Rate sensitive real estate and consumer, plus the banks push bourse to a fresh all-time high; Pinnacle posts results after ...
Investors are sifting through a slew of corporate earnings reports to assess how businesses may have been affected by U.S.
Now, it’s worth noting Stock Advisor’s total average return is 1,039% — a market-crushing outperformance compared to 181 % ...
3h
AAP Newsroom on MSNAustralian shares hit new highs as funds flow to minersCommodity price strength has underpinned a rotation of investor funds in global miners, helping push Australia's share market ...
In a conference call, AMD CEO Lisa Su (pictured) admitted that the export controls have been problematic for the company. “AI business revenue declined year-over-year as U.S. export restrictions ...
Major indexes fell Tuesday as stocks gave back a chunk of the previous session's gains amid ongoing concerns about tariffs and the economic outlook.
StockStory.org on MSN7h
Aflac (NYSE:AFL) Misses Q2 Sales TargetsSupplemental insurance provider Aflac (NYSE:AFL) in Q2 CY2025, with sales falling 5.1% year on year to $4.16 billion. Its non ...
StockStory.org on MSN7h
QuidelOrtho’s (NASDAQ:QDEL) Q2 Earnings Results: Revenue In Line With Expectations, Stock SoarsHealthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) in Q2 CY2025, but sales fell by 3.6% year on year to $613.9 million. On the other hand, the company’s full-year revenue guidance of $2.71 ...
StockStory.org on MSN7h
Toast’s (NYSE:TOST) Q2: Beats On RevenueRestaurant software platform Toast (NYSE:TOST) announced in Q2 CY2025, with sales up 24.8% year on year to $1.55 billion. Its ...
StockStory.org on MSN8h
Vestis (NYSE:VSTS) Posts Q2 Sales In Line With EstimatesUniform rental provider Vestis Corporation (NYSE:VSTS) in Q2 CY2025, but sales fell by 3.5% year on year to $673.8 million.
U.S. stocks have stumbled since the start of August, and a number of Wall Street strategists are warning that this might be ...
StockStory.org on MSN9h
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6%Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported in Q2 CY2025, but sales were flat year on year at $213.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results